Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer

Inclusion Criteria:

A. Subjects who are asymptomatic and scheduled to undergo routine screening mammography

OR

B. Subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care imaging modalities

AND

C. Subjects has a prior mammogram and have been diagnosed with extremely or heterogeneously dense breast tissue (Density C or D)

Exclusion Criteria:

Male by birth.
Individual is less than 30 and greater than 70 years old.
Contraindication to bilateral mammography or MRI
Subjects who are unable to read, understand and execute the informed consent procedure.
Subjects who have had mammography ultrasound or MRI examination performed on the day of the study prior to MIRA scan.
Subjects who have significant existing breast trauma.
Subjects who have undergone lumpectomy/mastectomy.
Subjects who have undergone breast reduction or breast augmentation.
Subjects who have undergone any other type of breast surgery, excluding surgical biopsy.
Subjects who have large breast scar / Breast deformation
Subjects who have undergone a breast needle biopsy or a surgical biopsy within the 6 month period prior to their intended enrollment into the study.
Subjects who have a temperature > 100° F (37.8C) degrees on the day of the MIRA imaging
Subjects who are pregnant or lactating
Subjects with known Raynaud's Disease
Subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session.
Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices
Subject with kidney failure
Subject with known allergy to gadolinium
Subject with a history of multiple contrast MRI scans (more than 4 MRI scans over the past two year)
Inmates (45 CFR 46.306) or mentally disabled individuals
Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy)
Subjects currently participating in another investigational clinical study
Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase